Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Lexicon Pharmaceuticals (LXRX) EBIAT (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed EBIAT for 4 consecutive years, with -$12.8 million as the latest value for Q3 2025.

  • Quarterly EBIAT rose 80.3% to -$12.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$99.6 million through Sep 2025, up 50.31% year-over-year, with the annual reading at -$116.2 million for FY2011, 14.19% down from the prior year.
  • EBIAT for Q3 2025 was -$12.8 million at Lexicon Pharmaceuticals, down from $3.3 million in the prior quarter.
  • The five-year high for EBIAT was $3.3 million in Q2 2025, with the low at -$64.8 million in Q3 2024.